Coherus Oncology, Inc.

For continuing operations, gross product revenues by significant customers as a percentage of total gross product revenues were as follows: Three Months Ended Six Months Ended June 30, June 30, 2026 2025 2026 2025 McKesson Corporation 42% 44% 40% 45%Cencora, Inc. 40% 39% 41% 37%Cardinal Health, Inc. 16% 15% 18% 17% Product Sales Discounts and AllowancesThe total provision related to sales made in the prior period was $(13.0) million and $(8.7) million for the three months ended June 30, 2026 and 2025, respectively.

The Company’s net revenue from continuing operations was as follows: Three Months Ended March 31, (in thousands) 2026 2025LOQTORZI $ 11,803 $ 7,348Other revenue 507 251 Total net revenue $ 12,310 $ 7,599 For continuing operations, gross product revenues by significant Customers as a percentage of total gross product revenues were as follows: Three Months Ended March 31, 2026 2025 McKesson Corporation 37% 46%Cencora, Inc. 42% 33%Cardinal Health, Inc. 20% 20% Product Sales Discounts and AllowancesChargebacks and discounts for prompt payment are recorded as a reduction in trade receivables, and the remaining reserve balances are classified as current liabilities on the condensed consolidated balance sheets.In connection with the sales of the CIMERLI ophthalmology franchise and the YUSIMRY franchise in 2024 and the UDENYCA franchise in 2025, the Company retained and continued to be responsible for sales discounts and allowance liabilities incurred prior to March 1, 2024 for CIMERLI, June 26, 2024 for YUSIMRY and April 11, 2025 for UDENYCA.

McKesson Corporation 43 % 43 %

McKesson Corporation 44 % 48 % 44 % 43 %

For continuing operations, gross product revenues by significant customers as a percentage of total gross product revenues were as follows: Three Months Ended Six Months Ended June 30, June 30, 2026 2025 2026 2025 McKesson Corporation 42% 44% 40% 45%Cencora, Inc. 40% 39% 41% 37%Cardinal Health, Inc. 16% 15% 18% 17% Product Sales Discounts and AllowancesThe total provision related to sales made in the prior period was $(13.0) million and $(8.7) million for the three months ended June 30, 2026 and 2025, respectively.

The Company’s net revenue from continuing operations was as follows: Three Months Ended March 31, (in thousands) 2026 2025LOQTORZI $ 11,803 $ 7,348Other revenue 507 251 Total net revenue $ 12,310 $ 7,599 For continuing operations, gross product revenues by significant Customers as a percentage of total gross product revenues were as follows: Three Months Ended March 31, 2026 2025 McKesson Corporation 37% 46%Cencora, Inc. 42% 33%Cardinal Health, Inc. 20% 20% Product Sales Discounts and AllowancesChargebacks and discounts for prompt payment are recorded as a reduction in trade receivables, and the remaining reserve balances are classified as current liabilities on the condensed consolidated balance sheets.In connection with the sales of the CIMERLI ophthalmology franchise and the YUSIMRY franchise in 2024 and the UDENYCA franchise in 2025, the Company retained and continued to be responsible for sales discounts and allowance liabilities incurred prior to March 1, 2024 for CIMERLI, June 26, 2024 for YUSIMRY and April 11, 2025 for UDENYCA.

Cencora, Inc. 36 % 43 %